DDInter1164 DDInter1729
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes. Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. This may be due to the sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood levels of the compound without inducing gastrointestinal effects, where the drug is excreted in the bile and then reabsorbed from the intestines. While its full mechanism of action is not fully understood, sulindac is thought to primarily mediate its action by inhibiting prostaglandin synthesis by inhibiting COX-1 and COX-2.
Metformin {u} (Compound) causes {v} (Side Effect) Pancreatitis
Pancreatitis {u} (Side Effect) is caused by {v} (Compound) Sulindac
Metformin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phentermine
Phentermine {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Sulindac
Metformin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nifedipine
Nifedipine {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Sulindac
Metformin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phentermine
Phentermine {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Sulindac
Metformin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triamterene
Triamterene {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Sulindac
Metformin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nifedipine
Nifedipine {u} (Compound) causes {v} (Side Effect) Alopecia
Alopecia {u} (Side Effect) is caused by {v} (Compound) Sulindac
Metformin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nabumetone
Nabumetone {u} (Compound) palliates {v} (Disease) osteoarthritis
osteoarthritis {u} (Disease) is palliated by {v} (Compound) Sulindac
Metformin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nabumetone
Nabumetone {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Nonsteroidal Anti-inflammatory Compounds {u} (Pharmacologic Class) includes {v} (Compound) Sulindac
Metformin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Bortezomib {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Sulindac
Metformin {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is associated with {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Sulindac
Metformin (Compound) causes Pancreatitis (Side Effect) and Pancreatitis (Side Effect) is caused by Sulindac (Compound)
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Sulindac (Compound)
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Sulindac (Compound)
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Sulindac (Compound)
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Triamterene and Triamterene (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Sulindac (Compound)
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine (Compound) causes Alopecia (Side Effect) and Alopecia (Side Effect) is caused by Sulindac (Compound)
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Nabumetone and Nabumetone (Compound) palliates osteoarthritis (Disease) and osteoarthritis (Disease) is palliated by Sulindac (Compound)
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Nabumetone and Nabumetone (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) and Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) includes Sulindac (Compound)
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Sulindac (Compound)
Metformin (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is associated with CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Sulindac (Compound)